LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Image Analysis Module Detects Cancers at the Time of Surgery

By LabMedica International staff writers
Posted on 26 May 2022
Print article
Image: NIO Laser Imaging System (Photo courtesy of Invenio Imaging)
Image: NIO Laser Imaging System (Photo courtesy of Invenio Imaging)

A new image analysis module based on deep learning allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary treatment of a diffuse glioma, providing cancer detection where they really need it and dramatically improving brain tumor surgery.

Invenio Imaging Inc.’s (Santa Clara, CA, USA) NIO Laser Imaging System uses Stimulated Raman Histology to image unprocessed tissue specimen without sectioning or staining, enabling histologic evaluation outside the laboratory. It has been used in over 2000 brain tumor procedures across multiple institutions in the US and in Europe. SRH allows three-dimensional imaging of thick specimens using optical sectioning and relies on laser spectroscopy to interrogate the chemical composition of the sample. As such, it does not require physical sectioning, (e.g. with a microtome on frozen or paraffin-embedded tissue) or dye staining, and it allows optical imaging of fresh tissue specimens with minimal tissue preparation.

In contrast to other laser spectroscopy techniques, SRH is unique in that it performs a spectroscopic measurement at each pixel and displays the results as a pseudo-color image, instead of a point spectrum. The NIO Laser Imaging System uses a high numerical aperture objective with 25x magnification and a 0.5mm scan width. Larger areas up to 10mm x 10mm can then be acquired by stitching multiple fields of view in a fully automated process. NIO images are natively digital and can be shared with existing IT infrastructure via a vendor-neutral DICOM interface. The NIO Glioma Reveal image analysis module now adds immediate decision support to the NIO Laser Imaging System by allowing the imaging of multiple samples from the resection cavity. Invenio has received the CE Mark for the NIO Glioma Reveal image analysis module, allowing neurosurgeons in the EU to use it to inform intraoperative decisions.

"By streamlining intraoperative tissue imaging, the NIO Laser Imaging System allows the imaging of multiple samples from the resection cavity. The NIO Glioma Reveal image analysis module now adds immediate decision support", said Chris Freudiger, PhD, co-founder and CTO of Invenio Imaging.

"Glioma Reveal provides cancer detection where we really need it, dramatically improving brain tumor surgery," added Prof. Dr. Jürgen Beck, Chair of Neurosurgery at the University of Freiburg.

"Applying reliable artificial intelligence to digital pathology appears to me, as a surgeon, to be the missing piece in the puzzle of rapid intraoperative histology-based decision-making," said Asst. Prof. Dr. Volker Neuschmelting, Vice-Chair of Neurosurgery at the University of Cologne.

"The NIO Laser Imaging System can also be combined with other important imaging techniques such as 5-ALA fluorescence to further improve brain tumor detection during surgery," explained Prof. Dr. Georg Widhalm, neurosurgeon at the University of Vienna.

Related Links:
Invenio Imaging Inc.

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.